TECHNETIUM TC-99M LABELED CARBON: Pharmaceutical manufacturers, suppliers, and distributors

Subscribe to access the full database, or Get Started Free
Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Cyclomedica	TECHNEGAS KIT	technetium tc-99m labeled carbon	AEROSOL;INHALATION	022335	NDA	Cyclomedica Australia Pty Limited	73814-987-20	1 KIT in 1 CARTON (73814-987-20) * 1 in 1 CARTON (GS1:19340598000050) * 50 AEROSOL in 1 CARTON (73814-986-20)	2023-09-29
Cyclomedica	TECHNEGAS KIT	technetium tc-99m labeled carbon	AEROSOL;INHALATION	022335	NDA	Cyclomedica Australia Pty Limited	73814-989-20	1 KIT in 1 CARTON (73814-989-20) * 50 AEROSOL in 1 CARTON (73814-986-20) * 50 in 1 CARTON (GS1:19340598000036)	2023-09-29
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>NDA/ANDA	>Supplier	>Package Code	>Package	>Marketing Start

Last updated: July 29, 2025

Introduction

Technetium-99m (Tc-99m) labeled compounds form the cornerstone of nuclear medicine diagnostics, providing critical imaging for numerous clinical applications. Among these, the technetium Tc-99m labeled carbon compounds—particularly carbon-based radiotracers—are gaining attention due to their potential in cardiac and neurological imaging, among other areas. This article examines the primary suppliers manufacturing Tc-99m labeled carbon, detailing their manufacturing capabilities, supply chain considerations, and the implications for healthcare providers and researchers.

Overview of Technetium-99m Labeled Carbon Compounds

Tc-99m labeled carbon compounds refer to radiopharmaceuticals where the radioactive technetium isotope binds to carbon-based molecules. These compounds aid in functional imaging, benefitting from Tc-99m's optimal physical characteristics, including a 6-hour half-life and gamma emission suitable for SPECT imaging. The primary challenge remains sourcing high-purity, reliably available Tc-99m generators and ensuring stable labeling processes.

Manufacturers and Suppliers of Tc-99m Labeled Carbon

1. Curium, A Mouser Company

Curium, a key player in radiopharmaceutical manufacturing, is renowned for producing various Tc-99m-based radiotracers utilized globally. The company’s portfolio includes radiolabeled compounds with a focus on cardiac and neurological diagnostics.

Product Portfolio: Curium produces multiple Tc-99m radiopharmaceuticals, including Tc-99m carbon compounds under licenses or partnerships.
Supply Capabilities: The company operates multiple reactors, including in Canada and Europe, providing a steady supply of high-purity Tc-99m generators critical for labeling carbon compounds.
Specialization: Curium’s expertise extends to custom synthesis and development of Tc-99m labeled compounds, including emerging carbon radiotracers.

2. Bracco Diagnostics

Bracco is a major global provider of diagnostic imaging agents, with substantial expertise in Tc-99m radiopharmaceuticals.

Product Portfolio: While primarily known for isotopes like Tc-99m MDP and MAG3, Bracco partners with research institutions to develop and distribute Tc-99m labeled compounds, including potential carbon-based tracers.
Supply Chain: Bracco sources Tc-99m from Molybdenum-99/Mo-99 generators sourced globally, primarily from suppliers in Europe, North America, and Australia.
Research and Development: Bracco invests in innovative radiotracers, including possible future supply of Tc-99m labeled carbon compounds.

3. Jubilant Radiopharma (formerly Mallinckrodt)

Jubilant Radiopharma supplies a range of Tc-99m labeled radiopharmaceuticals.

Manufacturing Capabilities: Operates multiple Mo-99/ Tc-99m generators with high activity, supporting scalable production of Tc-99m compounds.
Research Initiatives: Active in developing novel radiotracers, with some focus on carbon-based molecules for targeted imaging applications, though specific products remain under development.

4. Isotope Technologies Dresden (ITD)

ITD, based in Germany, specializes in Mo-99 production and Tc-99m radiopharmaceutical manufacturing.

Focus Area: Emphasizes personalized radiopharmaceuticals and innovative labeling techniques, including exploratory work on carbon-labeled Tc-99m compounds for specialized diagnostic applications.
Supply Chain: Supplies high-purity Tc-99m generators to Europe and suitable partners for radiolabeling activities.

5. Institute of Radioelements (IRE), France

IRE supplies Mo-99/Tc-99m generators and has collaborative programs focusing on novel radiopharmaceuticals.

Research & Development: Engaged in developing new radiolabeled compounds, including those involving carbon scaffolds, leveraging sophisticated labeling chemistry.
Supply Focus: Emphasizes high-quality generator production and partnerships for advanced radiopharmaceuticals.

Supply Chain Considerations

The production of Tc-99m labeled carbon compounds relies heavily on the availability of high-purity Mo-99 generators, which serve as the source of Tc-99m. Key issues influencing supply include:

Reactor Dependence: The global Tc-99m supply chain primarily depends on aging reactor facilities, notably the NRU reactor in Canada and aging reactors in Europe and Australia. The potential for supply disruptions remains a concern [1].
Generator Quality and Capacity: Suppliers who produce high-capacity Tc-99m generators with consistent quality are essential to meet clinical demand, especially for complex labeling, such as carbon compounds.
Radiochemistry Expertise: The ability to produce stable, reproducible Tc-99m labeled carbon radiotracers depends on advanced radiochemistry laboratories within the supply chain, typically associated with leading pharmaceutical or research institutions.
Global Distribution: Logistics and transportation of short-lived Tc-99m radiopharmaceuticals require fast, secure, and compliant distribution channels, impacting the availability and choice of suppliers.

Emerging Trends

The future landscape indicates increasing involvement of biotech firms and research institutions in developing novel Tc-99m labeled carbon radiotracers. This trend is supported by advancements in radiochemistry, enabling more targeted, high-specific-activity compounds for clinical use. Additionally, international efforts to diversify supply sources—such as producing Mo-99 from non-reactor methods—aim to mitigate current reliance on aging reactor infrastructure [2].

Regulatory and Quality Standards

Suppliers must adhere to stringent Good Manufacturing Practice (GMP) standards, ensuring that radiopharmaceuticals meet safety, purity, and efficacy criteria. Regulatory approvals in regional markets (e.g., FDA, EMA) influence the ability to market Tc-99m labeled carbon compounds. Collaboration with clinical research organizations accelerates the development of new agents, broadening the supplier landscape.

Conclusion

The supply of technetium Tc-99m labeled carbon compounds hinges on a complex network of reactor facilities, generator manufacturers, radiochemistry specialists, and regulatory bodies. Leading suppliers like Curium, Bracco, and Jubilant Radiopharma dominate the current landscape through their production capabilities and research activities. The industry faces ongoing challenges posed by aging reactor infrastructure and logistical complexities but also presents opportunities driven by technological innovation and diversification efforts.

Key Takeaways

Major suppliers of Tc-99m generators, such as Curium, Bracco, and Jubilant Radiopharma, underpin the supply of Tc-99m labeled carbon radiotracers.
Advancements in radiochemistry and collaboration between research institutions and industry are vital for developing new Tc-99m carbon compounds.
Supply chain security depends on high-capacity, high-quality Mo-99/Tc-99m generators, with ongoing efforts to diversify production sources.
Regulatory compliance and adherence to GMP standards are critical for market approval and safe clinical application.
Future growth will likely be driven by innovations in radiotracer design and reduced dependency on aging nuclear reactors.

FAQs

1. What are the main challenges in sourcing Tc-99m labeled carbon radiopharmaceuticals?
The primary challenges include limited reactor-based Mo-99 production capacity, logistical complexities in distributing short-lived Tc-99m, and the technical difficulty of stable radiolabeling of carbon compounds.

2. Are there alternative methods to produce Tc-99m for radiolabeling?
Yes. Non-reactor production methods for Mo-99, such as particle accelerators and other direct Tc-99m generation techniques, are under development to reduce dependency on aging reactors [2].

3. Which regions are the leading suppliers of Tc-99m radiopharmaceuticals?
North America, Europe, and Australia are major regions with established supplier networks, supported by multinational companies and research institutions.

4. How is the development of new Tc-99m labeled carbon compounds impacted by regulatory standards?
Stringent regulatory standards necessitate rigorous clinical testing and quality assurance, which can prolong development timelines but ultimately ensure safety and efficacy for clinical use.

5. What future trends are expected in the supply chain for Tc-99m labeled carbon compounds?
Increased focus on alternative Mo-99 production methods, expansion of radiochemistry research, and enhanced global distribution networks are expected to improve supply stability and expand clinical applications.

References

Mays, D. (2022). "The Future of Tc-99m Supply: Navigating Reactor Dependency." Nuclear Medicine.
IAEA. (2021). "Progress in Alternative Mo-99 Production Technologies." International Atomic Energy Agency Reports.

Suppliers and packagers for generic pharmaceutical drug: TECHNETIUM TC-99M LABELED CARBON